Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K van Besien

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|June 9, 2015
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipientsP Y Yew, H Alachkar, R Yamaguchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Bone Marrow Transplantation|June 18, 2013
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromesF Locke, R Agarwal, R Kunnavakkam, et al.
Bone Marrow Transplantation|November 17, 2009
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantationP J Shaughnessy, B J Bolwell, K van Besien, et al.
Blood|December 1, 1995
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantationS Giralt, J Hester, Y Huh, et al.
Blood|August 10, 1999
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantationD Przepiorka, T L Smith, J Folloder, et al.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Bone Marrow Transplantation|November 1, 1996
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donorsM Körbling, K W Chan, P Anderlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|June 9, 2015
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipientsP Y Yew, H Alachkar, R Yamaguchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 1, 1997
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patientsK van Besien, P Thall, M Korbling, et al.
Bone Marrow Transplantation|June 18, 2013
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromesF Locke, R Agarwal, R Kunnavakkam, et al.
Bone Marrow Transplantation|November 17, 2009
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantationP J Shaughnessy, B J Bolwell, K van Besien, et al.
Blood|December 1, 1995
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantationS Giralt, J Hester, Y Huh, et al.
Blood|August 10, 1999
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantationD Przepiorka, T L Smith, J Folloder, et al.
American Journal of Hematology|July 10, 2001
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemiaS Bibawi, D Abi-Said, L Fayad, et al.
Bone Marrow Transplantation|October 12, 1999
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantationD Przepiorka, I Khouri, C Ippoliti, et al.
Bone Marrow Transplantation|November 1, 1996
Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donorsM Körbling, K W Chan, P Anderlini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphomaD Przepiorka, K van Besien, I Khouri, et al.
Pageof 8